CDx Diagnostics Awarded Federal Supply Schedule Contract

 

Veterans now have access to WATS3D life-saving technology in the VA and community settings

 

SUFFERN, NY (December 15, 2020) – CDx Diagnostics has been awarded GSA Contract #36F79721D0050 for WATS3D, an AI-powered diagnostic platform developed to identify precancerous cells in the esophagus. WATS3D is now readily available to hospitals and clinics operated by the Veterans Administration, Department of Defense, Indian Health Services and federal prisons. Starting December 15, access to the WATS3D catalog and pricelist will be available to federal purchasers via the National Acquisition Center (NAC) and the GSA e-library here.

The Veterans Affairs Federal Supply Schedule (VA FSS) supports the healthcare requirements of the VA and other federal government agencies by providing customers with access to high-quality goods and services at the best commercial rate. As a VA approved contractor, 12.5 million veteran and active-duty members of the Military Health System now have access to the advanced sampling, screening, and analysis that WATS3D offers with the potential to prevent esophageal cancer.

One of the fastest growing and most fatal cancers in the US, esophageal cancer (EAC) develops from Barrett’s esophagus (BE), an acquired condition that occurs as a result of chronic recurrent acid-induced damage to the internal lining of the esophagus. WATS3D plays an important role in the early detection and prevention of EAC by using a unique combination of superior sampling, advanced 3D imaging and Artificial Intelligence analysis to determine the presence of BE and esophageal dysplasia in patients undergoing upper endoscopy. In large multicenter clinical trials, WATS3D has been found to significantly increase the detection rate of both BE and esophageal dysplasia compared to the traditional method of screening – the Seattle Protocol.

“What better way to honor and protect our veterans than to provide them with a life-saving technology,” says CDx Diagnostics CEO Bill Huffnagle. “CDx has worked diligently to create an avenue through which the WATS3D diagnostic platform can be made more readily available to our active duty military and veterans. We’re excited to be included in the Federal Supply Schedule with an opportunity to provide the evidence-based and cost-effective care of WATS3D both inside federal healthcare facilities and through the private sector.”

CDx has completed the five major pillars of evidence-based medicine for WATS3D, including Analytic Validity, Clinical Validity, Clinical Utility, Cost Effectiveness and Recommendations by Major Medical Societies. The technology has earned recognition from the American Society for Gastrointestinal Endoscopy (ASGE), the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and the American Foregut Society (AFS).

In 2019, the ASGE included WATS3D in its Standards of Practice Committee’s guideline for the screening and surveillance of BE. In 2020, the technology was deemed a safe and effective adjunct to forceps biopsies in the evaluation of BE, low-grade dysplasia, and high-grade dysplasia by SAGES and its Technology and Value Assessment Committee (TAVAC).

 

Get the latest posts in your email.

order kits Icon

Order Kits

Request additional test kits or patient materials.

Order Now

support icon

Support

Let us help you with questions about our products and services. 

Request Support

lab services icon

Laboratory Services

Learn about the diagnostic assessments used in evaluating specimens.

Learn More